Controversies in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 4, Issue 3, 1998, Pages 203-227

  Cohen, Mitchell B ^a,g   Seidman, Ernest ^b   Winter, Harland ^c   Colletti, Richard B ^d   Kirschner, Barbara ^e   Balistreri, William F ^a   Grand, Richard J ^f  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001297016     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-199808000-00005     Document Type: Short Survey

References (65)

1. Grand RJ, Ramakrishna J, Calenda KA. Inflammatory bowel disease in the pediatric patient. Gastroenterol Clin North Am 1995; 24:613-32.
2. Inflammatory bowel diseases. In: Roy CC, Silverman A, Alagille D, eds. Pediatric clinical gastroenterology. 4th ed. St. Louis: Mosby Year Book, 1995:427-93.
3. MacDermott RP. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 1994; 78:1207-31.
4. Dionne S, D'Agata ID, Hiscott J, Duhaime A, Seidman EG. Quantitative PCR analysis of TNF-α and IL-1b mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997;42:1557-66.
5. Yang H, McElree C, Roth C-P, Shanahan F, Targan SR, Rotter JI. Familial empirical risk for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993;34:517-24.
6. Peeters M, Nevens H, Baert F, Hiele M, De Meyer AM, Vlietinck R. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996;111:597-603.
7. Bayless TM, Tokayer AZ, Polito II JM, Quaskey SA, Mellits D, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members potential hereditary influences. Gastroenterology 1996;111:573-9.
8. Lee JCW, Lennard-Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology 1996;111:587-96.
9. Cottone M, Brignola C, Rosselli M, et al. Relationship between site of disease and familiar occurrence in Crohn's disease. Dig Dis Sci 1997;42:129-32.
10. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988;29:990-6.
11. Polito JM II, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6.
12. Yang H, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA Class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993;92:1080-4.
13. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter J. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995;109:440-8.
14. Plevy SE, Targan SR, Yang HY, Fernandez D, Rotter JI, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110:1053-60.
15. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106: 637-42.
16. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
17. Ohmen JD, Yang H-Y, Yamamoto KK, et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not ulcerative colitis. Hum Mol Genet 1996; 5:1679-83.
18. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genet 1996; 14:199-202.
19. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347: 1212-7.
20. Yang H, Rotter JI. The genetics of inflammatory bowel disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams & Wilkins 1994:32-64.
21. Toyoda H, Wang S-J, Yang H, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
22. Duerr RH, Chensny LJ, Wong CT, Neigut DA. Homozygosity of an HLA class II group haplotype is associated with pANCA-positive and familial ulcerative colitis. Gastroenterology 1995; 108:A812.
23. Targan SR, Landers CJH, MacDermott RP, Vidrich A. Perinuclear antineutrophil cytoplasmic antibodies are spontaneously produced by B-cells from involved and uninvolved mucosa of ulcerative colitis patients. J Immunol 1995;155:3262-7.
24. Winter HS, Landers CJ, Winkelstien A, Vidrich A, Targan SR. Antineutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994;125:707-11.
25. Seidman EG, Ruemmele R, Landers C, Gaiennie J, Braun J, Targan SR. Disease specific diagnostic accuracy of new serological tests in pediatric IBD. Gastroenterology 1997;112(4):A1087.
26. Eggena MP, Targan SR, Vidrich A, et al. Histone H1: the UC-specific PANCA target antigen. FASEB J 1996;10:463.
27. Shanahan F, Duerr R, Landers C, et al. Neutrophil autoantibodies in ulcerative colitis: a family study with evidence for genetic heterogeneity. Gastroenterology 1992;103:456-61.
28. Eggena M, Targan SR, Iwanczyk L, Vidrich A, Gordon LK, Braun J. Phage display cloning and characterization of an immunogenic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol 1996;156:4005-11.
29. Satsangi J, Landers C, Welsh K, Koss K, Targan S, Jewell DP. ANCA and HLA genes in North European patients with ulcerative colitis. Gastroenterology 1996;110:A1009.
30. Vecchi M, Gionchetti P, Bianchi MB, et al. pANCA and development of pouchitis in ulcerative colitis patients after protocolectomy and ileoanal pouch anastomosis. Lancet 1994;334:886-7.
31. Sandborn WJ, Landers CJ, Tremaine SJ, Targan SR. Anti-neutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal-anastomosis. Am J Gastroenterol 1995;90: 740-7.
32. Fleshner PR, Plevy SE, Landers CJ, Targan SR. A rise in PANCA titre after ileal pouch anal anastomosis for ulcerative colitis may predict early pouchitis. Gastroenterology 1996;110:A907.
33. Sandbom WJ, Landers CJ, Steiner BL, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibody (ANCA) is unexpectedly high in patients with treatment-resistant, left-sided ulcerative colitis (UC). Mayo Clin Proc 1996;71:431-6.
34. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease, Clin Diagn Lab Immunol 1996:32:219-26.
35. Ruemmele FM, Dubinsky M, Targan S, Barun J, Seidman E. Specificity of a new serologic test for pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1997;25:A448
36. Vasiliauskas E, Plevy SE, Landers CJ, et al. Perinuclear cytoplasmic antibodies (pANCA) in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-9.
37. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995;24(3):475-507.
38. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
39. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344-67.
40. Sartor RB. Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Aliment Pharmacol Ther 1996;10(suppl 2):36-42.
41. Sartor RB, Rath HC, Lichtman SN, van Tol EA. Animal models of intestinal and joint inflammation. Baillieres Clin Rheum 1996;10: 55-76.
42. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol 1990;132:1111-9.
43. Whorwell PJ, Holdstock G, Whorwell GM, Wright R. Bottle feeding, early gastroenteritis, and inflammatory bowel disease. BMJ 1979;1:382.
44. Wurzelman JI, Lyles CM, Sandier RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994;39:555-60.
45. Subhani J, Montgomery SM, Thompson N, Ebrahim S, Wakefield AJ, Pounder RE. Childhood risk factors for inflammatory bowel disease using a twin case control method. Gut 1996;39:A59.
46. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994;344:508-10.
47. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease following in-utero measles virus exposure. Lancet 1996;348: 515-7.
48. Lewin J, Dhillon AP, Sim R, Mazure G, Pounder RE, Wakefield AJ. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995;36:564-69.
49. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39: 345-53.
50. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071-3.
51. Feeney M, Clegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997;350:764-6.
52. Theofilopoulos AN. The basis of autoimmunity: part 1. mechanisms of aberrant self-recognition. Immunol Today 1995;16:90-8.
53. Snook J. Are the inflammatory bowel diseases autoimmune disorders? Gut 1990;31:961-3.
54. McFarland HF. Complexities in the treatment of autoimmune disease. Science 1996;274:2037-8.
55. Ina K, Binion DG, West GA, Dobrea GM, Fiocchi C. Crohn's disease (CD) mucosal T-cells are resistant to apoptosis. Gastroenterology 1995;108:A841.
56. Seidman EG, Hanson DG, Walker WA. Increased permeability to polyethylene glycol 4000 in rabbits with experimental colitis. Gastroenterology 1986;90:120-6.
57. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
58. Hollander D. The intestinal permeability barrier: a hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992;27:721-6.
59. Hollander D, Vadheim CM, Brettholz E, Peterson GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor. Ann Intern Med 1986;105:883-5.
60. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's diesase and their healthy relatives. Gastroenterology 1989;97:927-31.
61. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relative of patients with Crohn's disease? Gastroenterology 1993;104;1627-32.
62. Howden CW, Gillanders I, Morris AJ, Duncan A, Danesh B, Russell RI. Intestinal permeability in patients with Crohn's disease and their first-degree relatives. Am J Gastroenterol 1994;89:1175-6.
63. 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand J Gastroenterol 1989;24:993-8.
64. Ruttenburg D, Young GO, Wright JP, Isaacs S. PEG-400 excretion in patients with Crohn's disease, their first-degree relatives, and healthy volunteers. Dig Dis Sci 1992;37:705-8.
65. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992;33:320-3.